Auste­do, Teva's bright spot as it ex­e­cutes turn­around, fails two Touret­te's tri­als

It was all go­ing so well. Last week, Te­va in­vestors saw the light at the end of the tun­nel, af­ter Is­rael’s largest drug­mak­er hand­some­ly beat Wall Street sales ex­pec­ta­tions by $100 mil­lion — fol­low­ing years of de­cline, pre­cip­i­tat­ed by falling rev­enue, le­gal costs and mount­ing debt.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.